Results 11 to 20 of about 12,265 (153)

Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study.

PLoS ONE, 2020
PurposeTo evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in prior ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD) enrolled in the LUMINOUS™ study.Patients and methodsLUMINOUS, a 5 ...
Frank G Holz, Angelo M Minnella, Raman Tuli, Pradeepa Yoganathan, Soumil Parikh, Robin Hamilton, LUMINOUS™ study group   +6 more
doaj   +1 more source

Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

Clinical Ophthalmology, 2021
Faye Horner, Peck Lin Lip, Bashar R Mohammed, William Fusi-Rubiano, Eesha Gokhale, Bushra Mushtaq, Randhir Chavan Birmingham & Midland Eye Centre, Birmingham, UKCorrespondence: Randhir ChavanBirmingham & Midland Eye Centre, Sandwell & West ...
Horner F, Lip PL, Mohammed BR, Fusi-Rubiano W, Gokhale E, Mushtaq B, Chavan R   +6 more
doaj  

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema

Journal of Ophthalmology, 2018
Purpose. To compare the visual and anatomic outcomes in patients with persistent diabetic macular edema (DME) who switched from ranibizumab to aflibercept with those who continued with previous ranibizumab therapy. Methods.
Ali Demircan, Zeynep Alkin, Ceren Yesilkaya, Gokhan Demir, Burcu Kemer   +4 more
doaj   +1 more source

Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s Fibroblasts

Biomolecules, 2019
The anti-fibrotic properties of ranibizumab have been well documented. As an antagonist to vascular endothelial growth factor (VEGF), ranibizumab works by binding and neutralizing all active VEGF-A, thus limiting progressive cell growth and proliferation.
Siti Munirah Md Noh, Siti Hamimah Sheikh Abdul Kadir, Sushil Vasudevan   +2 more
doaj   +1 more source

subfoveal choroidal thickness before and after intravitreal Ranibizumab injection in patients with choroidal neovascularization [PDF]

Al-Azhar International Medical Journal, 2023
Background: Ranibizumab is anti-vascular endothelial growth factor (anti-VEGF) agent made for intraocular use, like smaller antibody fragment that can penetrate retina. Intravitreal ranibizumab therapy has been accepted as a predominant treatment for CNV
Mahmoud Elabiad, Elsayed Elewah, Abd Elghany Abd Elghany   +2 more
doaj   +1 more source

The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients

Scientific Reports, 2021
The ZIPANGU study assessed the efficacy and safety of ranibizumab as a one loading dose + pro re nata (one + PRN) regimen with/without focal/grid laser among treatment-naïve patients suffering from macular edema (ME) following branch retinal vein ...
Toshinori Murata, Mineo Kondo, Makoto Inoue, Shintaro Nakao, Rie Osaka, Chieko Shiragami, Kenji Sogawa, Akikazu Mochizuki, Rumiko Shiraga, Yohei Ohashi, Takeumi Kaneko, Chikatapu Chandrasekhar, Akitaka Tsujikawa, Motohiro Kamei   +13 more
doaj   +1 more source

Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study.

PLoS ONE, 2020
PURPOSE:To assess the 1-year effectiveness, safety, and treatment patterns of ranibizumab in patients with myopic choroidal neovascularization (mCNV) enrolled in the LUMINOUS study.
Robin D Hamilton, Andreas Clemens, Angelo Maria Minnella, Timothy Y Y Lai, Hong Dai, Taiji Sakamoto, Chui Ming Gemmy Cheung, Nor Fariza Ngah, Cornelia Dunger-Baldauf, Frank G Holz, LUMINOUS study group   +10 more
doaj   +1 more source

Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

International Journal of Retina and Vitreous, 2019
Background ASP8232 is a potent and specific small molecule vascular adhesion protein-1 (VAP-1) inhibitor. This study evaluated the effect of ASP8232 on excess retinal thickness when given alone or in combination with ranibizumab in patients with center ...
Quan Dong Nguyen, Yasir J. Sepah, Brian Berger, David Brown, Diana V. Do, Alberto Garcia-Hernandez, Sunil Patel, Firas M. Rahhal, Yevgeniy Shildkrot, Ronny W. Renfurm, the VIDI Research Group   +10 more
doaj   +1 more source

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. [PDF]

PLoS ONE, 2015
To compare treatment patterns of intravitreal ranibizumab and aflibercept for the management of neovascular age-related macular degeneration (nAMD) in a real-world setting over the first 12 months of treatment.A proprietary clinical database was used to ...
Alberto Ferreira, Alexandros Sagkriotis, Melvin Olson, Jingsong Lu, Charles Makin, Fran Milnes   +5 more
doaj   +1 more source

Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia [PDF]

International Journal of Ophthalmology, 2017
AIM: To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014. METHODS: Study
Nur Afiqah Mohamad, Vasudevan Ramachandran, Patimah Ismail, Hazlita Mohd Isa, Yoke Mun Chan, Nor Fariza Ngah, Norshakimah Md Bakri, Siew Mooi Ching, Fan Kee Hoo, Wan Aliaa Wan Sulaiman   +9 more
doaj   +1 more source